In 2026, when Joseph Mauro sold Boca Biolistics to a Canadian private equity firm, the expectation was that the company’s growth would continue elsewhere. The prevailing belief was that life sciences companies outgrew Florida, eventually moving to established biotech hubs like Boston or San Diego. However, three years later, this conventional wisdom is being challenged.
The biotech landscape in Florida is undergoing a remarkable transformation. With nearly 100,000 jobs across 8,600 establishments represented by BioFlorida, and initiatives like the Miami Biotech Collective attracting close to 500 executives and investors, the state is proving to be a formidable player in the industry. Companies like Catalyst Pharmaceuticals, based in Coral Gables, are achieving significant milestones, such as clearing $500 million in annual revenue. The momentum is undeniable, and the shift away from traditional biotech hubs appears to be permanent.
The Challenges Ahead
Despite this impressive growth, Florida’s policy infrastructure has not yet caught up with the economic transformation. The gap between the two will determine whether the state can sustain this momentum or risk losing ground to other regions. As someone who has built a clinical research organization, biobank, and reference laboratory in Florida, Joseph Mauro identifies key areas where the state is losing out on potential deals.
Workforce and Regulatory Friction
One of the primary challenges is the clinical laboratory workforce pipeline, which often fails to deliver sufficient qualified personnel. This shortage can deter companies from relocating or expanding in Florida. Additionally, regulatory friction across various departments, such as the Department of Health, AHCA, and the Department of Business and Professional Regulation, adds unnecessary hurdles without enhancing safety. These issues can slow down the growth of biotech companies and make other states more attractive.
Capital and Financing Gaps
Another critical issue is the lack of scale-up phase capital, particularly for Series B through commercial-stage funding. Many Florida-based companies are being pulled to states that offer purpose-built financing instruments. This capital gap can hinder the growth and success of biotech companies in Florida, making it essential to address this issue to maintain the state’s competitive edge.
Solutions for Sustainable Growth
The good news is that these challenges are not insurmountable. There are clear steps Florida can take to close the gap and ensure the biotech industry continues to thrive. Reforming the Board of Clinical Laboratory Personnel framework, expanding apprenticeship and credentialing programs at state universities and colleges, and fostering direct partnerships with industry employers can significantly expand the talent pool needed by biotech companies.
A coordinated interagency review of processes for clinical research organizations, reference laboratories, and biospecimen operators can streamline regulations and accelerate sector growth. Reinvigorating programs like the James and Esther King Biomedical Research Program, along with operator-led commercialization partnerships at institutions like Scripps Florida, Max Planck Florida Institute, UF Scripps, and Sylvester Cancer Center, can multiply the return on existing state investments.
To address the capital gap, state-backed bridge financing, targeted tax credits, and pension-fund co-investment vehicles for life sciences can provide the necessary funding for biotech companies to scale up. These measures can help Florida retain its competitive edge and attract more companies to the state.
The Need for Operator Perspective
The policy framework guiding Florida’s biotech strategy needs the input of those who have built the companies from the ground up. Including the operator perspective on boards like the Board of Clinical Laboratory Personnel and the James and Esther King Biomedical Research Program Council can ensure that policies are practical and effective. This collaboration can help shape a biotech strategy that truly supports the industry’s growth and success.
The economic transformation of Florida’s biotech industry is already underway. The question is whether the state will build the necessary infrastructure to match this growth deliberately and while it still has the lead. The time to act is now, and with the right policies and investments, Florida can secure its position as a leading biotech hub for the next decade and beyond.
